Cover Image

Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen

ABSTRACTBackground Next generation, higher valency pneumococcal conjugate vaccines (PCVs) are assessed and licensed by comparing the immune response across serotypes shared with the PCVs that are standard of care for prevention of pneumococcal disease.Methods Using a previously qualified method we p...

Full description

Saved in:

Bibliographic Details
Main Authors:	Josiah Ryman (Author), Jeffrey R. Sachs (Author), Natalie Banniettis (Author), Thomas Weiss (Author), Maurice Ahsman (Author), Ka Lai Yee (Author), Jessica Weaver (Author)
Format:	Book
Published:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children
by: Josiah Ryman, et al.
Published: (2024)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
by: Yaru Shi, et al.
Published: (2023)

An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants
by: Shahrul Mt-Isa, et al.
Published: (2023)

Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Maria L. Avila-Aguero, et al.
Published: (2017)

Response to: Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
by: Javier Nieto Guevara, et al.
Published: (2018)

Invasive pneumococcal disease (IPD) in HIV infected patients in Israel since the introduction of pneumococcal conjugated vaccines (PCV): Analysis of a nationwide surveillance study, 2009-2014
by: Michal Chowers, et al.
Published: (2017)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children
by: Timothy J Chapman, et al.
Published: (2024)

Adult non-invasive pneumococcal pneumonia in Portugal is dominated by serotype 3 and non-PCV13 serotypes 3-years after near universal PCV13 use in children
by: Catarina Silva-Costa, et al.
Published: (2023)

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
by: Ann-Charlotte Fridh, et al.
Published: (2024)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021)

Changes in invasive pneumococcal disease serotypes in a regional area of Australia following three years of 7vPCV introduction
by: Fakhrul Islam, et al.
Published: (2012)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
by: Helen L. Stacey, et al.
Published: (2019)

The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019
by: Eiman Mokaddas, et al.
Published: (2021)

Vaccination status (PCV13) of children with pneumococcal meningitis
by: Seidullayeva, Aliya, et al.
Published: (2020)

Estimates on state-specific Pneumococcal Conjugate Vaccines (PCV) coverage in the private sector in the year 2012: Evidence from PCV utilization data
by: Habib Hasan Farooqui, et al.
Published: (2016)

Pediatric Invasive Pneumococcal Disease (IPD) in Yogyakarta, Indonesia: A Case Series
by: Eggi Arguni MD, PhD, et al.
Published: (2022)

Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants"
by: Jorge A. Gómez, et al.
Published: (2022)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
by: Patricia Izurieta, et al.
Published: (2022)

Is Pneumococcal Serotype Replacement Impending?
by: Chun-Yi Lu, et al.
Published: (2016)

Closing the pneumococcal conjugate vaccine (PCV) introduction gap: an archetype analysis of last-mile countries
by: Preetika Banerjee, et al.
Published: (2023)

A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)
by: Alvino Maestri, et al.
Published: (2024)

Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10
by: Germán Camacho Moreno, et al.
Published: (2020)

Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012-2018
by: Larisa Savrasova, et al.
Published: (2021)

Invasive pneumococcal infection due to serotype 15A after the pneumococcal conjugate vaccine implementation in Turkey
by: Ayşe Büyükcam, et al.
Published: (2017)

Comparison of pneumococcal conjugate vaccine (PCV-13) cellular immune responses after primary and booster doses of vaccine
by: Timothy J. Chapman, et al.
Published: (2020)

Reply to 'Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10'
by: Javier Nieto Guevara, et al.
Published: (2020)

Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
by: Derek Lytle, et al.
Published: (2023)

Impact of PCV10 on pediatric pneumococcal disease burden in Brazil: time for new recommendations?
by: Daniel Jarovsky, et al.
Published: (2023)

Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy
by: Paolo Castiglia, et al.
Published: (2017)

Tingkat Pengetahuan Orang Tua terhadap Penyakit Pneumonia dan Imunisasi Pneumococcal Conjugate Vaccine (PCV) di Indonesia
by: Erlika Saputri, et al.
Published: (2020)

A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants
by: R. Rupp, et al.
Published: (2019)

Invasive pneumococcal disease in relation to vaccine type serotypes
by: Paeton L. Wantuch, et al.
Published: (2019)

Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution
by: Patricia Izurieta, et al.
Published: (2018)

Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028)
by: Yasunori Ishihara, et al.
Published: (2023)

Immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to vietnamese children at 18 months of age
by: Rachel A Higgins, et al.
Published: (2021)

Mastoiditis with Streptococcus pneumoniae serotype 19A in one-dose PCV13 vaccinated three-month-old infant
by: B. Gülhan, et al.
Published: (2019)

A systematic review about Streptococcus Pneumoniae serotype distribution in children in mainland of China before the PCV13 was licensed
by: Shuang Lyu, et al.
Published: (2017)

Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review
by: Goran Bencina, et al.
Published: (2022)

Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?
by: Hoet Bernard, et al.
Published: (2010)

SEROTYPE CHARACTERISTIC OF PNEUMOCOCCI ISOLATED FROM PATIENTS WITH PNEUMOCOCCAL MENINGITIS
by: I. S. Koroleva, et al.
Published: (2012)